Loading...
•
Jun 30, 2022
Ocular Therapeutix Q2 2022 Earnings Report
Ocular Therapeutix reported a net revenue increase of 5% year-over-year, driven by DEXTENZA sales, and is progressing with its ophthalmology pipeline.
Key Takeaways
Ocular Therapeutix reported its second quarter 2022 financial results, with net revenue of $12.3 million, a 5% increase compared to the same period in 2021. DEXTENZA net product revenue reached $12.1 million, representing a 9% increase year-over-year. The company is advancing its ophthalmology pipeline, with interim data from the OTX-TKI clinical trial expected in the third quarter.
Net revenue for the second quarter was $12.3 million, a 5% increase year-over-year.
DEXTENZA net product revenue reached $12.1 million, a 9% increase year-over-year.
A net loss of $(18.8) million, or $(0.24) and $(0.25) per share on a basic and diluted basis, respectively, was reported for the quarter.
Interim data from the U.S.-based Phase 1 clinical trial of OTX-TKI for the treatment of wet AMD is expected in the third quarter.
Ocular Therapeutix
Ocular Therapeutix
Ocular Therapeutix Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.comCollaboration Revenue
CapyFin.com Forward Guidance
Ocular Therapeutix reiterated DEXTENZA annual net product revenue guidance for 2022 between $55 to $60 million, representing annual growth of approximately 26% to 38%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income